Lindapeps
Member
it becomes increasingly popular recently .
NOT a GLP-1. Amylin agonist, Eloralintide activates the amylin axis to extend weight loss.
Eliralintide dosed once-weekly, demonstrating up to ~20% weight loss in Phase 2 clinical trials with a complementary, non-incretin pathway that positions it for both monotherapy and combinatio used alongside GLP-1-based therapies.
Eli Lilly's attempt to own best in class Amylin agonist, think Retatrutide + Eloralintide for patients who've plateaued on Retatrutide alone.
NOT a GLP-1. Amylin agonist, Eloralintide activates the amylin axis to extend weight loss.
Eliralintide dosed once-weekly, demonstrating up to ~20% weight loss in Phase 2 clinical trials with a complementary, non-incretin pathway that positions it for both monotherapy and combinatio used alongside GLP-1-based therapies.
Eli Lilly's attempt to own best in class Amylin agonist, think Retatrutide + Eloralintide for patients who've plateaued on Retatrutide alone.
